<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090631</url>
  </required_header>
  <id_info>
    <org_study_id>1196</org_study_id>
    <nct_id>NCT05090631</nct_id>
  </id_info>
  <brief_title>The Role of Genetic Factors in the Development of Atopic Dermatitis in the Kazakh Population</brief_title>
  <official_title>Preventive and Personalized Medicine (2021-2023)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asfendiyarov Kazakh National Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asfendiyarov Kazakh National Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a GWAS study that aims to identify possible candidate genes associate to atopic&#xD;
      dermatitisby exploring single nucleotide polymorphism (SNP) in a group of atopic dermatitis,&#xD;
      in the Kazakh population. The investigators hypothesize that the careful phenotyping of the&#xD;
      subject sand matching with increase the power to find SNP significantly associate with atopic&#xD;
      dermatitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A genome-wide association study (GWAS) is an approach used in genetics research to associate&#xD;
      specific genetic variations with particular diseases. The method involves scanning the&#xD;
      genomes from many different people and looking for genetic markers that can be used to&#xD;
      predict the presence of a disease. Once such genetic markers are identified, they can be used&#xD;
      to understand how genes contribute to the disease and develop better prevention and treatment&#xD;
      strategies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 23, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of SNPs associated with atopic dermatitis</measure>
    <time_frame>1 year</time_frame>
    <description>Using GWAS to identify candidate genes associate with atopic dermatitis</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Experimental group:</arm_group_label>
    <description>Patients with atopic dermatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients without atopic dermatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <description>GWAS</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group:</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        KAZAKH POPULATION&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persons with various forms of a confirmed diagnosis of atopic dermatitis;&#xD;
&#xD;
          -  The age of the patients is from 18 to 45+ years;&#xD;
&#xD;
          -  Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs.&#xD;
&#xD;
          -  Persons who are able and willing to provide written informed consent;&#xD;
&#xD;
          -  Persons capable and willing to comply with the research protocol;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons under the age of 18;&#xD;
&#xD;
          -  Patients with severe concomitant systemic diseases, including cardiovascular,&#xD;
             respiratory, hepatic and renal failure&#xD;
&#xD;
          -  Patients with severe infectious processes (sepsis, abscess, hepatitis B and C, HIV)&#xD;
&#xD;
          -  Persons with mental illness.&#xD;
&#xD;
          -  Persons taking corticosteroid drugs, immunosuppressants within the last month;&#xD;
&#xD;
          -  Persons who, in the opinion of the researcher, are mentally or legally incapacitated,&#xD;
             which prevents obtaining informed consent;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Tuberculosis of any localization in the active phase and in history;&#xD;
&#xD;
          -  Severe and decompensated diseases of the liver and kidneys, cardiovascular system;&#xD;
&#xD;
          -  Severe and decompensated course of endocrine diseases;&#xD;
&#xD;
          -  Autoimmune diseases;&#xD;
&#xD;
          -  Systemic diseases;&#xD;
&#xD;
          -  Oncological diseases;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gulya Sarybaeva, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asfendiyarov Kazakh National Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gulya Sarybaeva, PhD</last_name>
    <phone>+77025840033</phone>
    <email>gksarybaeva@gmail.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asfendiyarov Kazakh National Medical University</investigator_affiliation>
    <investigator_full_name>Ildar Fakhradiyev</investigator_full_name>
    <investigator_title>Head of the Laboratory of Experimental Medicine</investigator_title>
  </responsible_party>
  <keyword>GWAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

